10x Genomics, Inc. TXG
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 150.67M | 151.04M | 150.84M | 166.03M | 149.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 150.67M | 151.04M | 150.84M | 166.03M | 149.00M |
| Cost of Revenue | 37.74M | 38.54M | 44.67M | 52.89M | 48.70M |
| Gross Profit | 112.93M | 112.50M | 106.18M | 113.15M | 100.31M |
| SG&A Expenses | 76.06M | 78.66M | 66.38M | 73.02M | 74.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 166.72M | 173.99M | 167.89M | 181.67M | 180.54M |
| Operating Income | -16.06M | -22.96M | -17.05M | -15.64M | -31.54M |
| Income Before Tax | -18.48M | -18.65M | -12.85M | -15.19M | -28.21M |
| Income Tax Expenses | 949.00K | -714.00K | 623.00K | 1.06M | -733.00K |
| Earnings from Continuing Operations | -19.43M | -17.93M | -13.47M | -16.25M | -27.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.43M | -17.93M | -13.47M | -16.25M | -27.47M |
| EBIT | -16.06M | -22.96M | -17.05M | -15.64M | -31.54M |
| EBITDA | -6.55M | -13.29M | -7.09M | -5.58M | -21.25M |
| EPS Basic | -0.15 | -0.14 | -0.11 | -0.13 | -0.22 |
| Normalized Basic EPS | -0.05 | -0.11 | -0.06 | -0.06 | -0.13 |
| EPS Diluted | -0.15 | -0.14 | -0.11 | -0.13 | -0.22 |
| Normalized Diluted EPS | -0.05 | -0.11 | -0.06 | -0.06 | -0.13 |
| Average Basic Shares Outstanding | 130.81M | 129.98M | 128.29M | 127.08M | 125.50M |
| Average Diluted Shares Outstanding | 130.81M | 129.98M | 128.29M | 127.08M | 125.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |